Skip to Main Content

The Faculty of Medicine - Microbiology and Molecular Genetics: Weisblum Yiska


Last updated February 2023 - Microbiology and Molecular Genetics

List of Publications

(1) Gaebler C, Dasilva J, Bednarski E, Muecksch F, Schmidt F, Weisblum Y, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infect Dis 2022;9(7).

(2) Poston D, Weisblum Y, Hobbs A, Bieniasz PD. VPS29 Exerts Opposing Effects on Endocytic Viral Entry. mBio 2022;13(2).

(3) Kastenhuber ER, Mercadante M, Nilsson-Payant B, Johnson JL, Jaimes JA, Muecksch F, et al. Coagulation factors directly cleave SARSCoV-2 spike and enhance viral entry. eLife 2022;11.

(4) Schmidt F, Muecksch F, Weisblum Y, Silva JD, Bednarski E, Cho A, et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. New Engl J Med 2022;386(6):599-601.

(5) Brown JA, Sanidad KZ, Lucotti S, Lieber CM, Cox RM, Ananthanarayanan A, et al. Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection. Gut Microbes 2022;14(1).

(6) Schmidt F, Weisblum Y, Rutkowska M, Poston D, Da Silva J, Zhang F, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 2021;600(7889):512-516.

(7) Mast FD, Fridy PC, Ketaren NE, Wang J, Jacobs EY, Olivier JP, et al. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. eLife 2021;10.

(8) Greaney AJ, Starr TN, Barnes CO, Weisblum Y, Schmidt F, Caskey M, et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun 2021;12(1).

(9) Ricardo-Lax I, Luna JM, Thao TTN, Le Pen J, Yu Y, Hoffmann H-, et al. Replication and single-cycle delivery of SARS-CoV-2 replicons. Sci 2021;374(6571):1099-1106.

(10) Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatziioannou T, et al. Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera from Individuals with Recent Seasonal Coronavirus Infection. Clin Infect Dis 2021;73(5):E1208-E1211.

(11) Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 2021;54(8):1853-1868.e7.

(12) Scheid JF, Barnes CO, Eraslan B, Hudak A, Keeffe JR, Cosimi LA, et al. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell 2021;184(12):3205-3221.e24.

(13) Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021;592(7855):616-622.

(14) Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591(7851):639-644.

(15) Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol 2020;58(12).

(16) Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, et al. Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants. eLife 2020;9:1.

(17) Alfi O, From I, Yakirevitch A, Drendel M, Wolf M, Meir K, et al. Human nasal turbinate tissues in organ culture as a model for human cytomegalovirus infection at the mucosal entry site. J Virol 2020;94(19).

(18) Ramanathan A, Weintraub M, Orlovetskie N, Serruya R, Mani D, Marcu O, et al. A mutation in POLR3E impairs antiviral immune response and RNA polymerase III. Proc Natl Acad Sci U S A 2020;117(36):22113-22121.

(19) Barnes CO, West AP, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell 2020;182(4):828-842.e16.

(20) Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020;584(7821):437-442.

(21) Schmidt F, Weisblum Y, Muecksch F, Hoffmann H-, Michailidis E, Lorenzi JCC, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 2020;217(11).

(22) Weisblum Y, Oiknine-Djian E, Vorontsov OM, Haimov-Kochman R, Zakay-Rones Z, Meir K, et al. Erratum: Correction for Weisblum et al., "zika virus infects early-and midgestation human maternal decidual tissues, inducing distinct innate tissue responses in the maternal-fetal interface(Journal of Virology (2017) 91:4 (e01905-e01916) DOI: 10.1128/JVI.01905-16). J Virol 2019;93(22).

(23) Oiknine-Djian E, Weisblum Y, Panet A, Wong HN, Haynes RK, Wolfa DG. The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2018;62(7).

(24) Weisblum Y, Oiknine-Djian E, Zakay-Rones Z, Vorontsov O, Haimov-Kochman R, Nevo Y, et al. APOBEC3A is upregulated by human cytomegalovirus (HCMV) in the maternal-fetal interface, acting as an innate anti-HCMV effector. J Virol 2017;91(23).

(25) Glasner A, Oiknine-Djian E, Weisblum Y, Diab M, Panet A, Wolf DG, et al. Zika virus escapes NK cell detection by upregulating major histocompatibility complex class I molecules. J Virol 2017;91(22).

(26) Weisblum Y, Oiknine-Djian E, Vorontsov OM, Haimov-Kochman R, Zakay-Rones Z, Meir K, et al. Zika virus infects early- and midgestation human maternal decidual tissues, inducing distinct innate tissue responses in the maternal-fetal interface. J Virol 2017;91(4).

(27) Enk J, Levi A, Weisblum Y, Yamin R, Charpak-Amikam Y, Wolf DG, et al. HSV1 MicroRNA Modulation of GPI Anchoring and Downstream Immune Evasion. Cell Rep 2016;17(4):949-956.

(28) Vitenshtein A, Weisblum Y, Hauka S, Halenius A, Oiknine-Djian E, Tsukerman P, et al. CEACAM1-Mediated Inhibition of Virus Production. Cell Rep 2016;15(11):2331-2339.

(29) Yamin R, Lecker LSM, Weisblum Y, Vitenshtein A, Le-Trilling VTK, Wolf DG, et al. HCMV vCXCL1 Binds Several Chemokine Receptors and Preferentially Attracts Neutrophils over NK Cells by Interacting with CXCR2. Cell Rep 2016;15(7):1542-1553.

(30) Weisblum Y, Panet A, Zakay-Rones Z, Vitenshtein A, Haimov-Kochman R, Goldman-Wohl D, et al. Human cytomegalovirus induces a distinct innate immune response in the maternal-fetal interface. Virology 2015;485:289-296.

(31) Seidel E, Le VTK, Bar-On Y, Tsukerman P, Enk J, Yamin R, et al. Dynamic Co-evolution of Host and Pathogen: HCMV Downregulates the Prevalent Allele MICA*008 to Escape Elimination by NK Cells. Cell Rep 2015;10(6):968-982.

(32) Berger AA, Gil Y, Panet A, Weisblum Y, Oiknine-Djian E, Gropp M, et al. Transition toward human cytomegalovirus susceptibility in early human embryonic stem cell-derived neural precursors. J Virol 2015;89(21):11159-11164.

(33) Weisblum Y, Panet A, Haimov-Kochman R, Wolf DG. Models of vertical cytomegalovirus (CMV) transmission and pathogenesis. Semin Immunopathol 2014;36(6):615-625.

(34) Nachmani D, Zimmermann A, Oiknine Djian E, Weisblum Y, Livneh Y, Khanh Le VT, et al. MicroRNA Editing Facilitates Immune Elimination of HCMV Infected Cells. PLoS Pathog 2014;10(2).

(35) Weisblum Y, Panet A, Zichria Z-, Haimov-Kochman R, Goldman-Wohl D, Ariel I, et al. Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ culture. J Virol 2011;85(24):13204-13213.